SAL-061

N/A

Report date: 2026/03/27 20:01:50

Base Information

Drug NameSAL-061
Drug Alias NameYOLT-101SAL-061SAL061
ClassificationCell and gene therapy > Gene therapy > Gene editing > Base editingCell and gene therapy > Gene therapy > LNP
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHyperlipoproteinemia Type II
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Yaotang Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesYaotang (Nanjing) Biotechnology Co LtdFirst Affiliated Hospital Bengbu Medical CollegeRenji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine +[5] 
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaHyperlipoproteinemia Type II
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A